Portfolio
2
companies
.png)
Antiverse
Antiverse develops AI-designed therapeutic antibodies for challenging disease targets using computational platforms and in-house laboratories.
Houdini Bio
Houdini Bio develops software that redesigns therapeutic DNA so the body does not attack it.
SCVC led the pre-seed round with backing from Deep Science Ventures and Cambridge Enterprise VC to help the startup expand its team and partnerships.
"Cellular machinery still rejects these therapies, limiting long-term effectiveness and forcing costly, unsafe doses. Our platform introduces a vital shift from trial-and-error screening to repeatable, engineering-driven DNA design,"
The financing was supported by new investors including InnoSpark alongside returning backers such as the Development Bank of Wales.
"This is the most comprehensive validation of our platform thus far. While identifying antibodies to GPCRs has traditionally been a complex and time-intensive process requiring expensive specialist technology and training, we have demonstrated that Antiverse’s drug discovery platform can achieve this in a fraction of the time and cost. GPCRs are commercially interesting targets associated with various indications, and these antibodies offer a path to first in vivo results and can potentially be our first assets. I would like to thank our investors, this funding will enable us to continue to develop these assets in-house with our academic collaborators."
-20webclip.png)
